Praluent (alirocumab) is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is an injectable medication belonging to a class of drugs known as PCSK9 inhibitors [2]. Praluent is typically prescribed for adults with very high LDL cholesterol levels who have not achieved their targets with statins, or for those with certain genetic conditions that cause high cholesterol [1][3].
How does Praluent work to lower cholesterol?
Praluent works by targeting the PCSK9 protein in the body [2]. PCSK9 is a protein that binds to LDL receptors on the surface of liver cells and promotes their degradation [4]. By inhibiting PCSK9, Praluent allows more LDL receptors to remain on the liver cell surface [4]. These increased receptors then capture and remove more LDL cholesterol from the bloodstream, thereby lowering overall LDL cholesterol levels [4].
What is the typical dosage and administration for Praluent?
Praluent is administered as a subcutaneous injection every two weeks or monthly, depending on the prescribed dosage [1]. Common dosages include 75 mg and 150 mg [1]. The medication is usually injected into the thigh, abdomen, or upper arm [1].
What are the potential side effects of Praluent?
Common side effects associated with Praluent include upper respiratory tract infection, flu-like symptoms, and injection site reactions such as redness, itching, or bruising [1]. Less common but more serious side effects can occur and medical attention should be sought if any concerning symptoms arise [1].
When does the Praluent patent expire?
The patent exclusivity for Praluent is a complex area due to multiple patents covering the drug and its uses. Information from DrugPatentWatch.com indicates that Praluent has several patents associated with it, with various expiry dates [5]. Some patents related to the drug substance and formulation may expire in the mid-to-late 2020s, while others related to methods of use could extend further [5]. For precise details on specific patent expiry dates and potential market entry of generics or biosimilars, consulting resources like DrugPatentWatch.com is recommended [5].
How does Praluent compare to other cholesterol-lowering medications like statins?
Praluent is generally considered more potent than statins in lowering LDL cholesterol [3]. While statins work by reducing the liver's production of cholesterol, Praluent enhances the removal of LDL cholesterol from the blood [3][4]. It is often used in combination with statins for patients who require additional LDL reduction [3].
What are the clinical trial results for Praluent?
Clinical trials for Praluent, such as the ODYSSEY program, have demonstrated significant reductions in LDL cholesterol levels [3]. These studies have also evaluated the drug's impact on cardiovascular events. For example, the ODYSSEY OUTCOMES trial showed that Praluent, when added to maximally tolerated statin therapy, reduced the risk of major adverse cardiovascular events in patients who had recently experienced an acute coronary syndrome [6].
Can Praluent be used by patients with genetic high cholesterol conditions?
Yes, Praluent is indicated for patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), which are genetic disorders characterized by extremely high LDL cholesterol levels [1][3].
What is the price of Praluent and is it covered by insurance?
The cost of Praluent can vary, and it is a high-cost medication [7]. It is typically covered by most insurance plans, though co-pays and deductibles may apply [7]. Patients are often encouraged to check with their insurance provider and explore manufacturer co-pay assistance programs if available [7].
Who manufactures Praluent?
Praluent is manufactured by Sanofi and Regeneron Pharmaceuticals [1].
What are the regulatory approvals for Praluent?
Praluent has received approval from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1][8]. These approvals are based on extensive clinical data demonstrating its efficacy and safety profile for lowering LDL cholesterol [6][8].
Sources:
[1] https://www.praluent.com/
[2] https://www.drugpatentwatch.com/blogs/blog/pcsks9-inhibitors-explained
[3] https://www.drugpatentwatch.com/drugs/praluent
[4] https://www.drugpatentwatch.com/blog/praluent-mechanism-of-action
[5] https://www.drugpatentwatch.com/drugs/praluent/patents
[6] https://www.drugpatentwatch.com/blog/praluent-clinical-trials
[7] https://www.drugpatentwatch.com/blog/praluent-cost-and-insurance
[8] https://www.regeneron.com/news/regeneron-and-sanofi-announce-fda-approval-praluent-alirocumab-new-ind-treating-primary-hyperlipidemia-and-mixed-dyslipidemia